Yes, Influenza and PPSV23 Vaccines Can Be Given Simultaneously
The seasonal influenza vaccine and PPSV23 can be safely administered at the same time visit, given at different anatomic sites. This is explicitly supported by current ACIP guidelines and FDA labeling, with robust evidence demonstrating comparable immunogenicity and safety profiles.
Guideline-Based Recommendation
The 2024 ACIP influenza guidelines clearly state that inactivated influenza vaccines (IIVs) and recombinant influenza vaccines (RIVs) can be administered simultaneously or sequentially with other inactivated vaccines, including pneumococcal vaccines 1. Injectable vaccines given concomitantly should be administered at separate anatomic sites. The 2023 ACIP pneumococcal guidelines reinforce this, explicitly recommending routine coadministration of pneumococcal vaccines with other age-appropriate vaccines at the same visit for adults without specific contraindications 2.
FDA Labeling Considerations
The PPSV23 FDA label acknowledges that limited safety and immunogenicity data exist on concurrent administration with vaccines other than ZOSTAVAX 3. However, this statement reflects data availability at the time of labeling rather than a contraindication. The label does not prohibit coadministration with influenza vaccines.
Supporting Clinical Evidence
Multiple high-quality studies confirm the safety and effectiveness of simultaneous administration:
A 2025 study in 480 adults aged ≥60 years (including those with chronic diseases) demonstrated non-inferiority for both immunogenicity and safety when IIV4 and PPSV23 were given simultaneously versus separately 4. Adverse event rates were comparable (0.96% vs 1.47%), with most being mild.
A 2024 Korean retrospective cohort study of 2.9 million elderly patients found that concomitant vaccination was not associated with higher risk of most adverse events compared to sequential administration. In fact, concomitant vaccination showed lower risks for allergic reactions, neuritis, and pneumonia 5.
A 2018 Japanese randomized trial in 162 adults ≥65 years demonstrated non-inferiority of simultaneous versus sequential administration for pneumococcal antibody responses, with no increase in adverse reactions 6.
A 2017 phase III trial (N=334) in France and Belgium met all co-primary endpoints, showing non-inferiority for both vaccine immunogenicity when coadministered 7.
Practical Implementation
When administering both vaccines simultaneously:
- Give injections at separate anatomic sites (e.g., different arms)
- If using high-dose or adjuvanted influenza vaccines (HD-IIV or aIIV), which may cause more local reactions, administer in different limbs when possible 1
- Expect slightly higher rates of local injection site pain with coadministration, though this is generally mild and self-limited 7
- Document both vaccines with separate administration sites in the medical record
Clinical Advantages
Coadministration offers significant practical benefits:
- Improved vaccine uptake by reducing required visits
- Particularly valuable for elderly patients and those with mobility limitations
- Aligns with annual influenza vaccination visits for eligible adults
Important Caveats
- This recommendation applies to inactivated influenza vaccines only. Live attenuated influenza vaccine (LAIV) has different considerations for coadministration with other live vaccines 1
- For patients receiving multiple adjuvanted vaccines, while data support coadministration, providers should be aware that limited data exist on simultaneous administration of multiple non-aluminum adjuvant-containing vaccines 1
- The immunogenicity data specifically support coadministration; there is no evidence that separating the vaccines provides any clinical advantage
Bottom line: Administer both vaccines at the same visit in different anatomic sites to maximize protection and improve vaccination coverage.